Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific

International Journal of Epidemiology

Volumn 41, Issue 1, 2012, Pages 43-54

  Hamers, Raph L ^a   Oyomopito, Rebecca ^b,c   Kityo, Cissy ^d   Phanuphak, Praphan ^e   Siwale, Margaret ^f   Sungkanuparph, Somnuek ^g   Conradie, Francesca ^h   Kumarasamy, Nagalingeswaran ⁱ   Botes, Mariette E ^j   Sirisanthana, Thira ^k   Abdallah, Saade ^l   Li, Patrick C K ^m   Ngorima, Nicoletta ⁿ   Kantipong, Pacharee ^o   Osibogun, Akin ^p   Lee, Christopher K C ^q   Stevens, Wendy S ^h   Kamarulzaman, Adeeba ^r   Derdelinckx, Inge ^s   Chen, Yi Ming Arthur ^t   Schuurman, Rob ^s   Van vugt, Michèle ^a   Rinke de wit, Tobias F ^a   Njovu, C ^f   Labib, M ^u   Menke, J ^v   Sanne, I ^h   Wallis, C L ^h   Hardman, M ^w   Wellington, M ⁿ   Luthy, R ⁿ   Mandaliya, K ^l   Jao, I ^l   Dolan, M ^x   Namayanja, G ^d,y   Nakatudde, L ^d,y   Kiconco, M ^d,y   Abwola, M ^d,y   Mugyenyi, P ^d,y   Ndembiz, N ^z   Kaleebu, P ^z   Akanmu, S ^p   Wensing, A M ^s   Sigaloff, K ^a   Straatsma, E ^a   Lee, M P ^m   Wong, K H ^aa   Saghayam, S ⁱ   Pujari, S ^ab   Joshi, K ^ab   Merati, T P ^ac   Yuliana, F ^ac   Low, L L ^q   Ong, L Y ^r   Mustafa, M ^ad   Nordin, N ^ad   Ditangco, R ^ae   Bantique, R O ^ae   Wong, W W ^t   Yang, Y W ^t   Sirivichayakul, S ^e   Piyavong, B ^g   Praparattanapan, J ^k   Kambua, P ^o   Choi, J Y ^af   Han, S H ^af   Ratanasuwan, W ^ag   Sriondee, R ^ag   Kantor, R ^ah   Sohn, A H ^ai   Messerschmidt, L ^ai   Singtoroj, T ^ai   Cooper, D A ^b   Law, M G ^b   Jiamsakul, A ^b   Zhou, J ^b   more..

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^e THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^f Lusaka Trust Hospital   (Zambia)

^g MAHIDOL UNIVERSITY   (Thailand)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^j Muelmed Hospital   (South Africa)

^k CHIANG MAI UNIVERSITY   (Thailand)

^l Department of Obstetrics and Gynaecology   (Kenya)

^m QUEEN ELIZABETH HOSPITAL   (Hong Kong)

ⁿ Newlands Clinic   (Zimbabwe)

^o Chiang Rai Regional Hospital   (Thailand)

^p LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

^q HOSPITAL SUNGAI BULOH   (Malaysia)

^r UNIVERSITY OF MALAYA   (Malaysia)

^s UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^t NATIONAL YANG MING UNIVERSITY   (Taiwan)

^u Coptic Hospital ^*  (Zambia)

^v KARA Clinic and Laboratory   (Zambia)

^w Acts Clinic   (South Africa)

^x Mater Misericordiae Hospital   (Kenya)

^y JOINT CLINICAL RESEARCH CENTER   (Uganda)

^z UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^aa Integrated Treatment Centre   (China)

^ab Institute of Infectious Diseases   (India)

^ac UDAYANA UNIVERSITY   (Indonesia)

^ad HOSPITAL RAJA PEREMPUAN ZAINAB II   (Malaysia)

^ae RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^af Yonsei University College of Medicine   (South Korea)

^ag MAHIDOL UNIVERSITY   (Thailand)

^ah BROWN UNIVERSITY   (United States)

^ai TREAT Asia   (Thailand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

COHORT ANALYSIS; DRUG RESISTANCE; HEALTH MONITORING; HEALTH RISK; HEALTH SURVEY; HUMAN IMMUNODEFICIENCY VIRUS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA SOUTH OF THE SAHARA; ANTIVIRAL RESISTANCE; ARTICLE; ASIA; DRUG SURVEILLANCE PROGRAM; FEMALE; FOLLOW UP; FUNDING; GENOTYPE; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NON PROFIT ORGANIZATION; OUTCOME ASSESSMENT; PHARMACCESS AFRICAN STUDIES TO EVALUATE RESISTANCE; PRIORITY JOURNAL; THERAPEUTICS RESEARCH EDUCATION AND AIDS TRAINING IN ASIA;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ASIA; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; PACIFIC ISLANDS; POPULATION SURVEILLANCE; PROGRAM EVALUATION; YOUNG ADULT;

PACIFIC OCEAN; PACIFIC RIM; SUB-SAHARAN AFRICA;

EID: 84863383426     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyq192     Document Type: Article

References (29)

1. Joint United Nations Programme on HIV/AIDS and World Health Organization. AIDS Epidemic Update 2009. Geneva, Switzerland. http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf (1 July 2010, date last accessed).
2. World Health Organization. Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector: Progress Report 2009. http://www.who.int/hiv/pub/-tuapr_2009_en.pdf (July 2010, date last accessed).
3. Braitstein P, Brinkhof MW, Dabis F et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006;367:817-24.
4. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005;41:217-24.
5. Jahn A, Floyd S, Crampin AC et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008;371:1603-11.
6. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach, 20 Revision. Geneva, 2006. http://www.who.int/hiv/pub/guidelines/artadultguidelines. pdf (October 2009, date last accessed).
7. Keiser O, Orrell C, Egger M et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008; 5:e148.
8. Gupta RK, Hill A, Sawyer AW et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-treated under WHO guidelines: a systematic review and meta-analysis. The Lancet Infect dis 2009;9:409-17.
9. Rahim S, Fredrick LM, da Silva BA, Bernstein B, King MS. Geographic and temporal trends of transmitted HIV-drug resistance among antiretroviral-naive subjects screening for two clinical trials in North America and Western Europe. HIV Clin Trials 2009;10: 94-103.
10. Wensing AM, van de Vijver DA, Angarano G et al. Prevalence of drug-resistant HIV-variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005;192:958-66.
11. Hamers RL, Derdelinkx I, Van Vugt M, Stevens W, Rinke de Wit TF, Schuurman R. The status of HIV-resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther 2008;13:625-39.
12. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008;13(Suppl. 2):1-13.
13. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-genetic subtypes and recombinants in 2004. AIDS 2006;20:W13-23.
14. Dumans AT, Soares MA, Machado ES et al. Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance. J Infect Dis 2004; 189:1232-38.
15. Gonzalez LM, Brindeiro RM, Aguiar RS et al. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother 2004;48:3552-55.
16. Kantor R, Katzenstein DA, Efron B et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005;2:e112.
17. Martinez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA. Role of genetic diversity amongst HIV-non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev 2008;10: 212-23.
18. Land S, Cunningham P, Zhou J et al. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods 2009;159: 185-93.
19. Zhou J, Kumarasamy N, Ditangco R et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005;38: 174-79.
20. McGowan CC, Cahn P, Gotuzzo E et al. Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol 2007;36: 969-76.
21. Bertagnolio S, Derdelinckx I, Parker M et al. World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther 2008;13(Suppl. 2): 49-57.
22. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003;31:298-303.
23. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007;4:e298.
24. Hamers RL, Siwale M, Wallis C et al. HIV-drug resistance mutations are present in 6 percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 2010;55:95-101.
25. Hamers RL, Kityo C, Siwale M et al. Cohort Profile: The PharmAccess African Studies to Evaluate Resistance Monitoring Study (PASER-M) - HIV-Drug Resistance in sub-Saharan Africa. XVIII International AIDS Conference, July 18-2010, Vienna, Austria. Abstract no THPE0236. 2010.
26. Hamers RL, Wensing AM, Siwale M et al. Prevalence of drug-resistant HIV-variants at initiation of standard first-line HAART in Africa. XVIII International HIV Drug Resistance Workshop. Fort Myers, Fl, USA. June 9-13, 2009. Abstract 155. p. 155.
27. Sungkanuparph S, Oyomopito R, Sirivichayakul S et al. HIV-drug resistance among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study (TASER-M). European AIDS Conference, 11- November 2009. Cologne, Germany.
28. Oyomopito R, Phanuphak P, Sungkanuparph S et al. Cohort profile: the TREAT Asia studies to evaluate resistance monitoring study (TASER-M) - HIV drug resistance in the Asia-Pacific. XVIII International AIDS Conference, July 18-23, 2010, Vienna, Austria. Abstract no THPE0443. 2010.
29. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008;13(Suppl. 2):15-23.